Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use FRUZAQLA safely and effectively. See full prescribing information for FRUZAQLA. FRUZAQLA® (fruquintinib) capsules, for oral use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.
- generic_name
- fruquintinib
- product_names
- fruquintinib
- ndc
- 63020-210, 63020-210-21, 63020-225, 63020-225-21
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en